Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody

Gerald L Denardo, Sally J. DeNardo, Kathleen R. Lamborn, Desiree S. Goldstein, Norman B. Levy, Jerry P. Lewis, Lois F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P McGahan, Stanley L. Mills, Sui Shen

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.

Original languageEnglish (US)
Pages (from-to)239-254
Number of pages16
JournalCancer Biotherapy and Radiopharmaceuticals
Volume13
Issue number4
StatePublished - 1998

Fingerprint

Radioimmunotherapy
B-Lymphocytes
Antibodies
Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Therapeutics
Karnofsky Performance Status
B-Cell Lymphoma
Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Denardo, G. L., DeNardo, S. J., Lamborn, K. R., Goldstein, D. S., Levy, N. B., Lewis, J. P., ... Shen, S. (1998). Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody. Cancer Biotherapy and Radiopharmaceuticals, 13(4), 239-254.

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody. / Denardo, Gerald L; DeNardo, Sally J.; Lamborn, Kathleen R.; Goldstein, Desiree S.; Levy, Norman B.; Lewis, Jerry P.; O'Grady, Lois F.; Raventos, Antolin; Kroger, Linda A.; Macey, Daniel J.; McGahan, John P; Mills, Stanley L.; Shen, Sui.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 13, No. 4, 1998, p. 239-254.

Research output: Contribution to journalArticle

Denardo, GL, DeNardo, SJ, Lamborn, KR, Goldstein, DS, Levy, NB, Lewis, JP, O'Grady, LF, Raventos, A, Kroger, LA, Macey, DJ, McGahan, JP, Mills, SL & Shen, S 1998, 'Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody', Cancer Biotherapy and Radiopharmaceuticals, vol. 13, no. 4, pp. 239-254.
Denardo, Gerald L ; DeNardo, Sally J. ; Lamborn, Kathleen R. ; Goldstein, Desiree S. ; Levy, Norman B. ; Lewis, Jerry P. ; O'Grady, Lois F. ; Raventos, Antolin ; Kroger, Linda A. ; Macey, Daniel J. ; McGahan, John P ; Mills, Stanley L. ; Shen, Sui. / Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody. In: Cancer Biotherapy and Radiopharmaceuticals. 1998 ; Vol. 13, No. 4. pp. 239-254.
@article{38a06fd1a4744245b90c85791c667327,
title = "Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody",
abstract = "Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28{\%} of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30{\%} after a mean of 4 doses, but interrupted therapy in only 10{\%} of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83{\%}) of the patients and was great enough, and durable enough, in 17 (57{\%}) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94{\%}) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.",
author = "Denardo, {Gerald L} and DeNardo, {Sally J.} and Lamborn, {Kathleen R.} and Goldstein, {Desiree S.} and Levy, {Norman B.} and Lewis, {Jerry P.} and O'Grady, {Lois F.} and Antolin Raventos and Kroger, {Linda A.} and Macey, {Daniel J.} and McGahan, {John P} and Mills, {Stanley L.} and Sui Shen",
year = "1998",
language = "English (US)",
volume = "13",
pages = "239--254",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

AU - Lamborn, Kathleen R.

AU - Goldstein, Desiree S.

AU - Levy, Norman B.

AU - Lewis, Jerry P.

AU - O'Grady, Lois F.

AU - Raventos, Antolin

AU - Kroger, Linda A.

AU - Macey, Daniel J.

AU - McGahan, John P

AU - Mills, Stanley L.

AU - Shen, Sui

PY - 1998

Y1 - 1998

N2 - Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.

AB - Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.

UR - http://www.scopus.com/inward/record.url?scp=7844233336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844233336&partnerID=8YFLogxK

M3 - Article

C2 - 10850360

AN - SCOPUS:7844233336

VL - 13

SP - 239

EP - 254

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -